肝硬化中的真菌失调
该研究通过横断面和纵向分析评估肝硬化患者肠道细菌与真菌失调,发现肝硬化存在显著真菌失调,抗生素和质子泵抑制剂对其影响不同,而拟杆菌门/子囊菌门比值可独立预测90天住院。
要点
- 肝硬化患者存在显著真菌失调,细菌与真菌多样性显著相关。
- 抗生素使用后细菌和真菌多样性显著降低,念珠菌相对丰度升高。
- 拟杆菌门/子囊菌门比值较低与较低住院率相关,可独立预测90天住院。
核心结论
- 肝硬化存在显著真菌失调,抗生素和质子泵抑制剂使用后变化不同,但其他情况下随时间稳定。
- 拟杆菌门/子囊菌门比值可独立预测肝硬化患者90天住院。
研究设计与样本
- 横断面研究纳入143例肝硬化患者和26例年龄匹配对照,随访90天。
- 纵向研究包括三项:肝硬化患者随访6个月;门诊肝硬化患者按标准治疗使用抗生素5天;肝硬化患者和对照使用奥美拉唑14天。
- 所有研究均分析粪便细菌和真菌图谱。
主要发现
- 横断面中细菌和真菌多样性显著相关;使用抗生素的门诊患者和培养阳性感染患者多样性最低。
- 未感染、门诊和对照组中细菌与真菌相关性复杂,但在感染患者中明显偏移。
- 90天随访中21%患者住院;拟杆菌门/子囊菌门比值较低与较低住院率相关。
- 纵向随访5天和6个月真菌和细菌图谱稳定;抗生素后细菌和真菌多样性显著降低,念珠菌相对丰度升高,固有细菌相对丰度降低。
- 奥美拉唑后细菌多样性和组成变化,但真菌指标保持稳定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cirrhotics have a high rate of infections, which are increasingly fungal or culture-negative in nature. While infected cirrhotics have bacterial dysbiosis, the role of fungi is unclear. We aimed to evaluate gut bacterial and fungal dysbiosis in cross-sectional and longitudinal analyses of outpatient and inpatient cirrhotics and prediction of hospitalisations. METHODS: Cross-sectional: Age-matched controls, outpatients (with/without antibiotics) and hospitalised uninfected, culture-negative and culture-positive cirrhotics were included and followed for 90 days. Longitudinal: Three studies were conducted: (1) cirrhotics followed over 6 months, (2) outpatient cirrhotics administered antibiotics per standard of care for 5 days and (3) cirrhotics and controls administered omeprazole over 14 days. In all studies, stool bacterial/fungal profiles were analysed. RESULTS: Cross-sectional: In 143 cirrhotics and 26 controls, bacterial and fungal diversities were significantly linked. Outpatients on antibiotics and patients with culture-positive infections had the lowest diversities. Bacterial and fungal correlations were complex in uninfected, outpatient and control groups but were markedly skewed in infected patients. 21% were admitted on 90-day follow-up. A lower Bacteroidetes/Ascomycota ratio was associated with lower hospitalisations. Longitudinal: Fungal and bacterial profiles were stable on follow-up (5 days and 6 months). After antibiotics, a significantly reduced bacterial and fungal diversity, higher Candida and lower autochthonous bacterial relative abundance were seen. After omeprazole, changes in bacterial diversity and composition were seen but fungal metrics remained stable. CONCLUSION: There is a significant fungal dysbiosis in cirrhosis, which changes differentially with antibiotics and proton pump inhibitor use, but is otherwise stable over time. A combined bacterial-fungal dysbiosis metric, Bacteroidetes/Ascomycota ratio, can independently predict 90-day hospitalisations in patients with cirrhosis. CLINICAL TRIAL NUMBER: NCT01458990.
引用
- Bajaj JS, Liu EJ, Kheradman R, et al. Fungal dysbiosis in cirrhosis. Gut. 2017. PMID: 28578302. doi:10.1136/gutjnl-2016-313170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。